Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:


Last Updated: February 7, 2023

Details for Patent: 9,149,477

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,149,477 protect, and when does it expire?

Patent 9,149,477 protects ZYDELIG and is included in one NDA.

This patent has forty-six patent family members in twenty countries.

Summary for Patent: 9,149,477
Title:5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
Abstract: Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below: ##STR00001##
Inventor(s): Kesicki; Edward A. (Bothell, WA), Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Bellevue, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Puri; Kamal Deep (Lynnwood, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA)
Assignee: ICOS Corporation (Indianapolis, IN)
Application Number:14/284,331
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,149,477

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No See Plans and Pricing See Plans and Pricing INHIBITION ON PI3K KINASE See Plans and Pricing
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing INHIBITION ON PI3K KINASE See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,149,477

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005245875 See Plans and Pricing
Australia 2009230739 See Plans and Pricing
Canada 2566609 See Plans and Pricing
China 101031569 See Plans and Pricing
China 102229609 See Plans and Pricing
Cyprus 1118493 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.